Results 21 to 30 of about 35,587 (246)
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics
Biomolecules, 2021 Isocitrate dehydrogenase (IDH1) catalyzes the reversible NADP+-dependent oxidation of isocitrate to α-ketoglutarate (αKG). IDH1 mutations, primarily R132H, drive > 80% of low-grade gliomas and secondary glioblastomas and facilitate the NADPH-dependent ...
Joi Weeks +5 more
doaj +1 more source
IDH1‐mutant cancer cells are sensitive to cisplatin and an IDH1‐mutant inhibitor counteracts this sensitivity [PDF]
The FASEB Journal, 2018 Introduction Isocitrate dehydrogenase 1 ( IDH1 ) is mutated in various types of human cancer and the presence of a mutation is associated with improved responses to irradiation and chemotherapy in solid tumor cells. Mutated IDH1 (IDH1
Khurshed, Mohammed +7 more
openaire +2 more sources
The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients. [PDF]
PLoS ONE, 2013 OBJECTIVE: Mutations in the gene encoding isocitrate dehydrogenease 1 (IDH1) occur in various hematopoietic tumors including acute myeloid leukemia (AML), myeloproliferative neoplasms and myelodysplastic syndromes.
Lixun Guan +6 more
doaj +1 more source
Epigenetics, 2020 Mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) lead to metabolic alterations and a sustained formation of 2-hydroxyglutarate (2-HG). 2-HG is an oncometabolite as it inhibits the activity of α-ketoglutarate-dependent dioxygenases such as ten ...
Christian Gerecke +4 more
doaj +1 more source
Mutant IDH1 is required for IDH1 mutated tumor cell growth
Oncotarget, 2012 Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. However, whether mutant IDH1 protein is required for maintaining IDH1 mutated tumor cell growth remains unknown.
Jin, Genglin +9 more
openaire +3 more sources
Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival. [PDF]
PLoS ONE, 2013 Recurrence and progression to higher grade lesions are characteristic behaviors of gliomas. Though IDH1 mutation frequently occurs and is considered as an early event in gliomagenesis, little is known about its role in the recurrence and progression of ...
Yu Yao +10 more
doaj +1 more source
Frontiers in Endocrinology, 2020 Aim: Isocitrate dehydrogenase 1 (IDH1) is key enzyme involved in cellular metabolism and DNA repair. Mutations in IDH1 occur in up to 25% of cholangiocarcinomas.
Li Su +5 more
doaj +1 more source
npj Precision Oncology, 2022 The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and strategies to overcome resistance are poorly understood.
James M. Cleary +11 more
doaj +1 more source
Recent advances of IDH1 mutant inhibitor in cancer therapy
Frontiers in Pharmacology, 2022 Isocitrate dehydrogenase (IDH) is the key metabolic enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG). Two main types of IDH1 and IDH2 are present in humans.
Wangqi Tian +7 more
doaj +1 more source